Gilead Sciences raised its annual product sales guidance following robust performance in its core HIV business, driven by strong Biktarvy demand and solid operational execution.

Eli Lilly posted significant revenue gains driven by unprecedented global demand for its blockbuster treatments Mounjaro and Zepbound, solidifying its leadership in the metabolic therapeutics market.

Boston Scientific trimmed its annual guidance for a second time, citing fallout from a recent cyber incident alongside persistent operational friction across global healthcare markets.